For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES) implantation, de-escalating dual antiplatelet therapy (DAPT) to P2Y12 inhibitor monotherapy is associated with lower ...

For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES ... compared the effects of de-escalating DAPT to ticagrelor monotherapy versus standard DAPT using data from ...

HealthDay News — For patients with acute coronary syndrome (ACS) undergoing drug-eluting stent (DES ... the effects of de-escalating DAPT to ticagrelor monotherapy vs standard DAPT using ...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.

New Delhi: In its latest drug alert, the apex drug regulatory body, the Central Drug Standard Control Organization (CDSCO), ...

Nevertheless, the new sub-analysis could provide a significant boost for Brilinta, as the data suggest treating patients for longer with the drug can prevent more from suffering a second ...

Ticagrelor monotherapy as used in the TWILIGHT ... to be safer than ticlopidine and stent thrombosis with the early drug-eluting stents seemed to be lessened with more prolonged DAPT.

In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the ...

In September 2024, the Company submitted a De Novo medical device application to the U.S. FDA requesting marketing approval to reduce the severity of perioperative bleeding in CABG patients on the ...

to ticagrelor monotherapy versus standard DAPT in patients with acute coronary syndrome (ACS) undergoing drug-eluting stint (DES). The results found that de-escalating DAPT to ticagrelor ...